Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
0.3888(c) 0.393(c) 0.401(c) 0.3901(c) 0.3906(c) Last
71 564 187 527 223 857 253 809 160 838 Volume
-0.31% +1.08% +2.04% -2.72% +0.13% Change
More quotes
Company
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
2017 NAVIDEA BIOPHARMACEUTICALS : to Present at Biotech Showcase 2018
2017 NAVIDEA BIOPHARMACEUTICALS : to Present at Biotech Showcase 2018
2017 NAVIDEA BIOPHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibi..
2017 NAVIDEA BIOPHARMACEUTICALS : to Present at LD Micro 10th Annual Main Event
2017 NAVIDEA BIOPHARMACEUTICALS : to Present at LD Micro 10th Annual Main Event
2017 NAVIDEA BIOPHARMACEUTICALS : to Present Late-Breaking Abstract at American Colle..
2017 NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
2017 NAVIDEA BIOPHARMACEUTICALS INC : Navidea Biopharmaceuticals, Inc. to Host Earnin..
2017 NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
2017 NAVIDEA BIOPHARMACEUTICALS : reports 3Q loss
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/09 Navidea Biopharm (NAVB) Presents At 10th Annual Biotech Showcase 2018 - Slide..
2017 Planned equity offering roundup - healthcare
2017 Healthcare events next week
2017 Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q3 2017 Results - ..
2017 Navidea Biopharm reports Q3 results
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Eric K. Rowinsky Chairman
Jed Andrew Latkin CFO, COO, Secretary & Treasurer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Mark I. Greene Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTICALS INC11.86%63
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.19%20 784
LONZA GROUP1.56%20 682
INCYTE CORPORATION-0.68%19 342
ALNYLAM PHARMACEUTICALS, INC.1.59%12 256